Way to Quit - Comparative Efficacy, Acceptance and Effectiveness of Health Incentive Structures
Specific Aim I: Compare the efficacy and effectiveness of 4 financial incentive structures
for improving "quit rates" (rates of prolonged smoking abstinence for 6 months): (a)
individual financial rewards, (b) individual deposit contracts, (c) cooperative rewards, and
(d) competitive deposit contracts
H1: Compared with usual care, all 4 incentive structures will increase quit rates
H2: Compared with individual financial rewards of equivalent size and schedule, individual
deposit contracts, cooperative rewards, and competitive contracts will each increase quit
H3: Group-oriented structures will increase quit rates significantly more than
Specific Aim II: Compare smokers' acceptance of these 4 financial incentive structures for
H4: Uptake rates of reward-based structures will be higher than of structures involving
H5: Uptake rates of group-oriented structures will be higher than of individual-oriented
Specific Aim III: Identify individual characteristics that modify incentive structures'
efficacy and acceptance
H6: Incentives will promote relatively greater quit rates among participants with fewer
H7: Incentives will promote relatively greater quit rates among participants with lower
H8: Higher-income persons will be relatively more likely to accept incentives requiring
Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment
Salivary cotinine or anabasine testing (metabolites of nicotine)
The primary measure of smoking cessation will be prolonged abstinence for 6 months, which will be measured by salivary cotinine testing or by urinary anabasine testing (for those participants using nicotine replacement therapy). Saliva samples will be analyzed using semi-quantitative immunochromatographic assay test strips at the University of Pennsylvania. Urine samples will be analyzed using gas chromatography at the Associated Regional and University Pathologists (ARUP) Lab, at the University of Utah.
at 6 months following the patient selected target quit date.
Scott Halpern, MD, Ph.D.
University of Pennsylvania, Department of Medicine, Pulmonary, Allergy and Critical Care
United States: Institutional Review Board
|University of Pennsylvania||Philadelphia, Pennsylvania 19104|